CPC A61K 31/426 (2013.01) [A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 47/54 (2017.08); A61K 47/542 (2017.08); A61K 47/547 (2017.08); A61K 47/548 (2017.08); A61K 47/64 (2017.08); A61K 49/0041 (2013.01); A61K 49/0043 (2013.01); A61K 49/0052 (2013.01); A61K 49/0056 (2013.01); A61K 51/04 (2013.01); A61K 51/0402 (2013.01); A61K 51/0489 (2013.01); A61K 51/088 (2013.01); C07C 323/52 (2013.01); C07D 207/416 (2013.01); C07K 5/08 (2013.01)] | 3 Claims |
1. A compound of the formula:
B-L-IA
or a salt thereof, wherein:
B is a ligand of prostate specific membrane antigen (PSMA), wherein the ligand is a urea of two amino acids, wherein the two amino acids are independently selected from asparagine, aspartic acid, cysteine, glutamic acid, lysine, glutamine, arginine, serine, ornithine, and threonine;
L is a divalent linker of 14 to 24 atoms in length, wherein the divalent linker comprises chains of carbon and oxygen atoms forming a polyoxyalkylene group and a divalent peptide comprising a phenylalanine residue and a tyrosine residue; and
IA is a fluorescent imaging agent.
|